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We previously reported that the ErbB2 oncoprotein prolongs and ampliﬁes growth factor signalling by impairing ligand-
dependent downregulation of hetero-oligomerised epidermal growth factor receptors. Here we show that treatment of A431
cells with different epidermal growth factor receptor ligands can cause growth inhibition to an extent paralleling ErbB2 tyrosine
phosphorylation. To determine whether such growth inhibition signiﬁes an interaction between the cell cycle machinery and
ErbB2-dependent alterations of cell signalling kinetics, we used MCF7 breast cancer cells (which express wild-type p53) to
create transient and stable ErbB2 transfectants (MCF7-B2). Compared with parental cells, MCF7-B2 cells are characterised by
upregulation of p53, p21
WAF and Myc, downregulation of Bcl2, and apoptosis. In contrast, MCF7-B2 cells co-transfected with
dominant negative p53 (MCF7-B2/Dp53) exhibit reduced apoptosis and enhanced growth relative to both parental MCF7-B2
and control cells. These data imply that wild-type p53 limits survival of ErbB2-overexpressing breast cancer cells, and suggest
that signals of varying length and/or intensity may evoke different cell outcomes depending upon the integrity of cell cycle
control genes. We submit that acquisition of cell cycle control defects may play a permissive role in ErbB2 upregulation, and
that the ErbB2 overexpression phenotype may in turn select for the survival of cells with p53 mutations or other tumour
suppressor gene defects.
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The molecular pathways controlling cell growth and death are
deeply intertwined, with gene products as diverse as Myc (Evan
et al, 1992; Harrington et al, 1994; Barone and Courtneidge,
1995; Packham et al, 1996; Kauffmann-Zeh et al, 1997), Raf
(Morrison et al, 1989; Pumiglia and Decker, 1997; Woods et al,
1997) and MAP kinase (Traverse et al, 1992; Ben-Levy et al,
1994; Marshall, 1995; Marte et al, 1995; Kimura et al, 1999) being
ﬁrmly implicated in both outcomes. By the same token, well-char-
acterised mitogens such as the epidermal growth factor receptor
(EGFR) and the ErbB2 (HER2/neu) oncoprotein have been causally
linked to cell growth inhibition and apoptosis (Gill and Lazar,
1981; Kawamoto et al, 1984; Filmus et al, 1985; Polet, 1990; Taglia-
bue et al, 1991; Armstrong et al, 1994; Harris et al, 1995; Kita et al,
1996). Since these molecules are often overexpressed in human
breast tumours (Sainsbury et al, 1985; Slamon et al, 1989) –
subtypes of which exhibit prominent apoptosis (Bodis et al,
1996; Liu et al, 1992) – a better understanding of their pathoge-
netic signiﬁcance could be relevant to anticancer drug
development.
We previously reported that growth arrest of 3T3 cells is
associated with catalytic activation of ErbB2 (Epstein et al,
1990), and more recently demonstrated that ErbB2 lengthens
and intensiﬁes mitogenic signalling by impairing ligand-depen-
dent EGFR downregulation (Huang et al, 1999). In addition,
we have shown that the functionally distinct EGFR ligands,
EGF and transforming growth factor-alpha (TGFa), exert differ-
ing effects on EGFR downregulation and hence on the duration
of ErbB2 co-activation: high concentrations of EGF initially
cause prolonged EGFR activation associated with ErbB2 hetero-
dimerisation, followed by eventual EGFR downregulation and
signal cessation; whereas TGFa fails to downregulate EGFR,
leading to sustained signalling (Gulliford et al, 1997; Ouyang
et al, 1999a). The possibility is thus raised that ErbB2 could
mimic the tumorigenic effects of TGFa in cancer cells by its
similar ability to prolong EGFR signalling.
The above-mentioned differential induction of growth stimula-
tion or inhibition by EGFR (Filmus et al, 1985; Polet, 1990;
Armstrong et al, 1994; Gulli et al, 1996) and ErbB2 (Tagliabue
et al, 1991; Harris et al, 1995; Kita et al, 1996) strongly suggests
an interaction between downstream signal duration (e.g. of MAP
kinase) and cell cycle control proteins (Traverse et al, 1992;
Marshall, 1995). To address the possibility that ErbB2-dependent
changes in signal duration may contribute to such differences in
cell fate, it is necessary to create cell systems in which the effects
of ErbB2 expression can be correlated with the function or
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show that the effects of ErbB2 on cell signalling kinetics are selec-
tively associated with induction of apoptosis in oestrogen-
responsive MCF7 human breast cancer cells – which, like most
hormone-sensitive cancers (Calefﬁ et al, 1994; Elledge et al,
1995; Berns et al, 2000), express wild-type p53 (Casey et al,
1991; Balcer-Kubiczek et al, 1995; Furuwatari et al, 1998) but
normally do not overexpress ErbB2 (Wright et al, 1997; Ferrero-
Pous et al, 2000; Pinto et al, 2001). Dominant negative knockout
of p53 converts growth inhibition to growth enhancement in
these ErbB2-transfected cells, suggesting that a p53 mutational
pathway could favour selection for ErbB2 gene ampliﬁcation
during tumour progression.
MATERIALS AND METHODS
Cell lines, reagents, antibodies, and immunoblotting
MCF7 and A431 cells were obtained from the American Type
Culture Collection (Rockville, MD, USA). Synthetic human EGF
and TGFa were purchased from Sigma. Activation-state-speciﬁc
EGFR antibodies, and antibodies to p53, Myc, Bcl2 and p21
WAF,
were purchased from Cambridge BioScience (Cambridge, UK).
Polyclonal antibodies to Tyr
1248- and Tyr
1222-phosphorylated
ErbB2 were developed and validated for receptor-speciﬁcity as
described previously (Epstein et al, 1992; Ouyang et al, 1998).
For immunoblotting studies, cells were lysed as previously
described (Gulliford et al, 1997): protein lysates were immediately
boiled for 5 min in sample buffer (6.7% sodium dodecyl sulfate,
30% glycerol, 62.5 mM Tris base pH 6.8, 0.01% bromophenol blue)
then loaded onto a 7.5% SDS-polyacrylamide gel. Samples were
electrophoresed and transblotted onto nitrocellulose as described
(Towbin et al, 1979).
Growth curves and apoptosis assays
Cell growth was measured using a multiwell colorimetric assay
based on sulphorhodamine B (SRB) spectrophotometric detection.
Conﬁrmation and quantiﬁcation of morphologic apoptosis was
performed using a Tdt-mediated dUTP nick-end labelling
(TUNEL) kit to directly detect DNA fragmentation in situ. Brieﬂy,
cells were plated and grown on glass slides, treated with ligand for
the required period, then ﬁxed in 4% paraformaldehyde for 30 min
at room temperature. The slides were washed with PBS three times,
after which the cells were permeabilised with 0.1% Triton-X-100 in
0.1% sodium citrate for 10 min. After washing, the cells were
covered in 50 ml of equilibration solution for 10 min, then covered
with 50 ml of labelling solution (Biovation) and incubated at 378C
for 1 h while light-protected. The slides were then washed, covered
in 10 ml counterstain for 10 min, and analysed using ﬂuorescence
microscopy.
Cell transfection
For calcium phosphate transfection, cells were seeded in 90 mm
diameter cell culture dishes at 5610
5 cells ml
71 24 h before the
transfection. One plate was required for each transfection experi-
ment; the monolayer normally grew to 80% conﬂuence by the
following day, and the medium was changed 3 h before the trans-
fection. Two sterile microfuge tubes were labelled for each
transfection experiment: to one tube was added 500 mlo f
26BBS (pH 6.95) and to the other tube was added 125 mlo f
1 M CaCl2,1 0 – 2 0 mg of recombinant plasmid DNA which
contained the relevant cDNA; distilled H2O was added to give a
ﬁnal volume of 500 ml. This was added to equal the volume of
26concentrated BBS using a sterile Pasteur pipette. At the same
time, ﬁltered air was passed through the 26BBS buffer
(pH 6.95) with a second Pasteur pipette, and the DNA mixture
was then incubated at room temperature for 20 min to allow preci-
pitation. The DNA/CaPO4 precipitate was mixed by inverting the
tube, and was added directly to a 10 ml cultured cell dish dropwise
with gentle shaking, and the cell culture incubated at 378C with 3%
CO2 overnight followed by washing with PBS and re-culturing in
fresh medium at 378C with 5% CO2.
Constructs and selection procedures
The well-characterised temperature-sensitive dominant negative
p53 construct (Kuerbitz et al, 1992; Slichenmeyer et al, 1993;
Zhang et al, 1994; Vasey et al, 1996) was kindly provided by Dr
B Vogelstein (Baker et al, 1990). For selection, transfected cells
were plated at 5610
4 cells/9 cm tissue culture dish with relevant
reagents: dominant negative p53 was selected with neomycin. The
wild-type ErbB2 construct, which is under the control of the Molo-
ney murine leukaemia virus LTR and contains the Ecogpt selectable
marker from E. coli (Di Fiore et al, 1987), was selected with HAT
(hypoxanthine, aminopterin and thymidine) as described by Mulli-
gan and Berg (1981). For double transfection a pool of six p53
dominant negative clones (Dp53) or p53 empty vector clones were
transfected with either ErbB2 or ErbB2 empty vector, and selected
with HAT medium for at least 6 weeks. Resistant colonies were
cloned and a pool of six clones was cultured with HAT medium
to amplify the cell number. For analysis, the cells were cultured
in normal medium for at least 2 weeks before the experiments were
performed. For morphologic analysis, cells were grown in plastic 8-
chamber containers (LabTek; Gibco) and the monolayers photo-
graphed using a Zeiss microscope. Growth experiments were
carried out in 96-well plates using quantiﬁcation of Hoechst dye
immunoﬂuorescence in six matched samples following 3 days
growth to assess cumulative DNA content.
RESULTS
Consistent with earlier reports (Gill and Lazar, 1981; Polet, 1990),
ligand stimulation experiments conﬁrm EGF-dependent growth
inhibition of sparsely-plated A431 cells (Figure 1A, upper panel).
The extent of growth inhibition correlates with the intensity of
equimolar ligand-dependent ErbB2 tyrosine phosphorylation as
detected by site-speciﬁc phosphoantibodies (Ouyang et al, 1998)
which conﬁrm greater ErbB2 tyrosine phosphorylation following
EGF stimulation (Figure 1A, lower panel). As reported previously,
this initial difference in ligand-dependent signal intensity is main-
tained and further exaggerated over the subsequent 12 h (Ouyang
et al, 1999a). Correlation of light microscopy with TUNEL assay
indicates that the growth-inhibitory effects of EGF in this context
are associated with increased apoptosis (Figure 1B).
The foregoing data do not distinguish whether the observed
growth inhibition is induced by ligand-dependent ErbB2 co-activa-
tion per se or, alternatively, by the downstream consequences of
growth factor signal prolongation induced by ligand-dependent
ErbB2 heterodimerisation. However, since our previous work
documented a marked prolongation of EGFR signalling by ErbB2
expression (Huang et al, 1999), we elected to test the latter hypoth-
esis by creating ErbB2 transfectants in cell lines differing solely in
terms of cell cycle control functionality. To this end, MCF7 human
breast cancer cells known to express both copies of the wild-type
p53 gene (Casey et al, 1991; Balcer-Kubiczek et al, 1995; Furuwatari
et al, 1998) were transiently transfected with ErbB2. As shown in
Figure 2A, ErbB2 expression in these cells induces increased immu-
noreactivity of both activated ErbB2 and EGFR, consistent with
previous studies (Huang et al, 1998, 1999), while also inducing
increased expression of p53, p21
WAF and Myc. Of note, ErbB2
expression is associated with reduced Bcl2 expression – an effect
reported previously following primary overexpression of p53
(Haldar et al, 1994). These effects on protein expression are accom-
panied by morphologic changes (membrane blebbing, chromatin
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(7), 1104–1109condensation) typical of apoptosis in ErbB2-transfected, but not
vector control, cells (Figure 2B). These ErbB2-dependent changes
in protein expression and morphology directly implicate ErbB2
in the activation of an apoptotic pathway.
To clarify whether the apoptosis-triggering effect of ErbB2 might
be at least partly related to its effects on signalling kinetics (i.e. as
opposed to an exclusive cell-killing effect of ErbB2 kinase activity),
stable MCF7 cell transfectants were created using either the wild-
type ErbB2 gene, the dominant-negative p53 mutant gene, or both.
As in the ErbB2 transient transfectants, stable overexpression of
ErbB2 selectively induces endogenous (wild-type) p53 protein over-
expression (Figure 3A, upper panel, left three lanes); as expected,
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Figure 1 Relative effects of EGF and TGFa on cell growth, growth inhi-
bition, and ErbB2 tyrosine phosphorylation of A431 cells. (A) Effects of dif-
ferential ligand treatment on cell growth, relative to growth of untreated
controls (upper ﬁgure) and to ligand-dependent ErbB2 tyrosine phosphor-
ylation (lower ﬁgure). In the upper ﬁgure, cells were plated at
1.5610
4 ml
71 seeding density and stimulated for 6 days with the respec-
tive ligand (EGF, solid columns; TGFa, open columns) prior to counting
using a sulphorhodamine-based assay as described. Nanomolar ligand con-
centrations are represented on the abscissa. The results are expressed as a
percentage change relative to control cell growth; error bars are based on
six measurements. The lower ﬁgure shows the corresponding short-term
effects of EGF and TGFa on ErbB2 Y
1222 phosphorylation: cells were trea-
ted for 5 min with EGF or TGFa at the indicated nanomolar concentration
prior to lysis, electrophoresis and immunoblotting using aPY
1222. The bands
were visualised using ECL. (B) Visualisation of cell death by light micro-
scopy and TUNEL assay (see Materials and Methods) associated with ligand
treatment. Twenty-four hours following attachment, cells were treated with
the respective ligands (2 nM) in serum-free medium. Typical low-power
views of triplicate plates are shown after 48 h treatment using light micro-
scopy (above) and ﬂuorescence microscopy (below).
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Figure 2 Effects of transient ErbB2 transfection on parental MCF7 cells.
(A) Effects of ErbB2 transfection on protein expression. Control (lane 1;
vector-only) and ErbB2-transfected cells (lane 2) were lysed and assessed
by immunoblotting. EGFR*, kinase-active epidermal growth factor receptor;
1248, ErbB2 tyrosine-phosphorylated at position 1248, detected by the ac-
tivation-speciﬁc aPY
1248 antibody (Ouyang et al, 1998). (B) Effects of ErbB2
expression on morphology and apoptosis of MCF7 human breast cancer
cells assessed using light microscopy. ErbB2 transfectants (at right) were
generated using a standard calcium phosphate transfection procedure fol-
lowed by neomycin selection. Mock transfectants containing empty plas-
mids are shown at left.
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immunoreactive p53 (Figure 3A, upper panel, right three lanes).
Irradiated control and ErbB2-transfected MCF7 cells exhibit a
normal increase in p21
WAF expression following X-irradiation
(Figure 3B, lower panel, left 6 lanes). In contrast, MCF7-Dp53 cells
sustain no immunodetectable rise in p21
WAF levels (Figure 3B,
lower panel, right 6 lanes), thus validating the functionality of
the dominant-negative p53 construct used in these experiments.
Of note, p21
WAF was not detectably overexpressed in stable
ErbB2-overexpressing cells (Figure 3B) unlike in transient transfec-
tants (Figure 2A), raising the possibility that prolonged ErbB2
overexpression induces clonal selection.
The four transfectant cell lines of interest – parental MCF7,
MCF7-B2, MCF7-Dp53, and MCF7-B2/Dp53 – were then
compared with respect to morphology and growth. Unlike parental
MCF7 cells which adopt a spread-out cell appearance suggesting
density-dependent growth inhibition (Figure 4A, upper left), all
of the other transfectants exhibit a crowded morphology. MCF7-
B2 cells also exhibit striking apoptosis (Figure 4A, lower left),
however, a feature which is absent from both the MCF7-Dp53
and MCF7-B2/Dp53 cells (Figure 4A, right upper and lower panels,
respectively). Cell growth as measured by Coulter counting was
increased in MCF7-Dp53 cells and reduced in MCF7-B2 cells rela-
tive to parental cell growth: MCF7-B2/Dp53 cells exhibit more
rapid growth than parental cells, though slower than MCF7-Dp53
cells (Figure 4B). Given the foregoing results, these data indicate
that the observed ErbB2-dependent effects on cell fate vary with
the functional status of p53, suggesting in turn that p53 may act
as a sensor for ErbB2-induced changes in cell signalling kinetics.
DISCUSSION
We previously showed that ErbB2 expression causes constitutive
EGF signalling by retarding downregulation of hetero-oligomerised
EGFR (Huang et al, 1999). This effect most likely relates to the
absence of motifs in the ErbB2 C-terminal tail for receptor inter-
nalisation and degradation (Sorkin et al, 1993; Baulida et al,
1996). Since human tumours exclusively overexpress the wild-type
ErbB2 rather than the transforming point mutant (Lemoine et al,
1990), a reasonable hypothesis is that tumour cells acquire a
growth advantage from wild-type ErbB2 overexpression, but that
this phenotype does not represent the primary transforming event
– implying the co-existence, that is, of at least one other molecular
defect within the tumour cells. This hypothesis is consistent with
numerous reports linking tumour cell ErbB2 overexpression and
p53 dysfunction (Horak et al, 1991; Mehta et al, 1995; Li et al,
1997) and identifying poor-prognosis clinical subgroups based on
concurrence of these phenotypes (Tsuda et al, 1998). Moreover,
our recent documentation of differential survival outcomes in
ErbB2-overexpressing breast cancers associated with different phos-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
p53
–28
–19 p21
C
o
n
t
r
o
l
B
2
 
v
e
c
t
o
r
B
2
p
5
3
D
p
5
3
D
v
e
c
t
o
r
p
5
3
D
/
B
2
–67
–50
C
o
n
t
r
o
l
C
o
n
t
r
o
l
B
2
 
v
e
c
t
o
r
B
2
 
v
e
c
t
o
r
B
2
B
2
p
5
3
D
p
5
3
D
p
5
3
D
v
e
c
t
o
r
p
5
3
D
v
e
c
t
o
r
p
5
3
D
/
B
2
p
5
3
D
/
B
2
RT RT RT RT RT RT
A
B
Figure 3 Effects of stable ErbB2 overexpression and/or p53 knockout on
MCF7 cell protein function as measured by expression of p53 and p21
WAF
in ErbB2 and/or mutant p53 transfectants and controls. (A) p53 immuno-
blot. Control, parental MCF7 cells; B2 vector, MCF7 transfected with vector
alone; B2, MCF7 transfected with vector containing ErbB2 cDNA; p53D,
MCF7 transfected with dominant negative mutant p53; p53D vector,
MCF7 transfected with dominant negative p53 and also with empty vector
used for ErbB2 studies; p53D/B2, MCF7 cells transfected with dominant ne-
gative mutant p53 and with ErbB2. B, p21
WAF immunoblot. As indicated by
the legend below, cells from even-numbered lanes received radiotherapy
(RT) with 0.1 Gy X-irradiation prior to lysis. Odd-numbered lanes repre-
sent the sample order described for the upper panel.
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Figure 4 Effects of ErbB2 overexpression and/or p53 knockout on
MCF7 cell morphology and growth. (A) Morphology of MCF7 cell variants
characterised by light microscopy. Top left, parental MCF7 cells; top right,
MCF7 transfected with mutant p53; lower left, MCF7 transfected with wild-
type ErbB2; lower right, MCF7 co-transfected with both mutant p53 and
wild-type ErbB2. (B) Cell growth of MCF7 variants following 3 days growth.
Error bars represent standard errors of the mean based on six identical
samples for each cell line. Abbreviations are as above.
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notion of multiple signalling pathways governing tumour growth
phenotypes.
Given that the p53 checkpoint prevents cell-cycle progression
when activated (Casey et al, 1991; Yin et al, 1992; Wyllie et al,
1995) and that the duration of growth factor signalling inﬂuences
whether cells proliferate or arrest (Traverse et al, 1992; Marshall,
1995), the present study suggests a model of cell signal sensing
which is differentially perturbed by ErbB2 depending upon the
functional p53 status. Other studies have concluded that the main
in vitro and in vivo consequences of p53 mutation on cell growth
relate to enhanced proliferation rather than to reduced apoptosis
(Nikiforov et al, 1996; Tyner et al, 1999). Our data suggest a more
complex interpretation of p53 function as a co-variable within the
cell growth machinery; this is consistent with the surprising ﬁnding
in human tumours that p53 mutation is often associated with
increased, rather than decreased, apoptotic indices (van Slooten
et al, 1999). In the context of tumour progression, it is important
to note that apoptosis could represent a mechanism of clonal selec-
tion for more aggressive cell lineages, rather than simply indicating
a benign tumour-suppressive function.
Reductions in mitogenic signal intensity may normally cause
cells to arrest and/or differentiate, whereas signal prolongation
may trigger differentiation or death (Traverse et al, 1992;
Dolmetsch et al, 1997). According to this paradigm, apoptosis
may be inducible by forced cell cycle progression in the presence
of activated checkpoints (Polet, 1990). Abrogation of p53 function
by mutation could thus prevent cells from sensing an abnormally
prolonged signal, leading to loss of growth arrest, reduced apopto-
sis and differentiation, and consequent outgrowth of less
differentiated cells. In contrast, ErbB2-dependent impairment of
EGFR downregulation both prolongs and intensiﬁes growth factor
signalling (Huang et al, 1999), an outcome associated with the
increased apoptosis reported here. Such an effect of ErbB2 might
be expected to be short-lived, given that selection for apoptotic
resistance should be rapid (Balcer-Kubiczek et al, 1995). Acquisi-
tion of a p53 defect in this context would cause mutant cells to
‘perceive’ mitogenic signals as short despite ErbB2-dependent
signal prolongation – leading to apoptotic resistance, dedifferen-
tiation and clonal outgrowth.
Human tumours could thus evolve from an interplay between
progressive ErbB2 overexpression and acquisition of cell-cycle
control defects including, though not necessarily limited to, p53
mutations. We therefore submit that human tissues with cell-cycle
control defects (De Cremoux et al, 1999; Prevo et al, 1999) may
gain a growth advantage by prolonging and intensifying ambient
growth factor signals via ErbB2 upregulation, and that tumour cells
overexpressing ErbB2 may in turn clonally select for cell-cycle
checkpoint loss (Li et al, 1997).
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